• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

    5/15/24 4:05:00 PM ET
    $ENGN
    $NAMS
    $NKTX
    $PCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENGN alert in real time by email

    enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson.

    "We are pleased to welcome Paul and Wouter to our Board of Directors. Their breadth of biopharma industry experience across research, corporate management and finance equips them well to serve as Board members of enGene, particularly as we look to the potential expansion of our pipeline across additional urological indications and move towards our planned BLA filing for EG-70 in the first quarter of 2026," said Jason Hanson, Chief Executive Officer of enGene.

    "enGene's non-viral DDX platform holds great promise in realizing the Company's vision of mainstreaming genetic medicines, and I believe the design of EG-70 for ease of use makes it uniquely well-matched to the needs of community urologists caring for patients with NMIBC," remarked Mr. Hastings. "The Company is well-positioned for success, and I look forward to working with the management team to execute its vision."

    Mr. Joustra said, "I'm thrilled to join enGene's Board of Directors. There continues to be a profound unmet need in NMIBC, and I believe EG-70's product profile stands out and supports a potential future role as the intravesical therapy of first choice for community and high-volume urology clinics across the country. The Company has laid out a compelling strategic plan and is looking forward to several exciting milestones, including the planned announcement of interim data from its pivotal Phase 2 Legend study mid-year as well as the planned expansion of the EG-70 program into new indications."

    Mr. Hastings has served as the President, Chief Executive Officer, and a member of the board of directors of Nkarta, Inc. (NASDAQ:NKTX) since February 2018. Prior to that, he served as President, Chief Executive Officer, and Director of the publicly traded, clinical-stage biopharmaceutical company OncoMed Pharmaceuticals, Inc. from January 2006 until January 2018. In August 2013, he was elected Chairman of the board of directors of OncoMed and served in that role until January 2018. Prior to joining OncoMed, Mr. Hastings was President, Chief Executive Officer, and Director of QLT, Inc., a publicly traded biotechnology company dedicated to the development and commercialization of innovative ocular products, from February 2002 to September 2006. From 2000 to 2002, Mr. Hastings served as President, Chief Executive Officer, and Director of Axys Pharmaceuticals, Inc., which was acquired by Celera Corporation in 2001. Mr. Hastings was also previously the President of Chiron Biopharmaceuticals, a division of Chiron Corporation, President and Chief Executive Officer of LXR Biotechnology, and he held a variety of management positions of increasing responsibility at Genzyme Corporation, including President of Genzyme Therapeutics Europe and President of Worldwide Therapeutics.

    Mr. Hastings previously served on the board of directors of Relypsa, a publicly traded biotechnology company acquired by Galencia AG, as Chairman of the board of directors of Proteolix, Inc., a privately held biopharmaceutical company acquired by Onyx Pharmaceuticals, Inc., on the board of directors of ViaCell, Inc., a publicly traded biotechnology company sold to Perkin Elmer, and as a director of ViaCyte, Inc., a privately held regenerative medicine company acquired by Vertex Pharmaceuticals, Inc. Mr. Hastings currently serves as Chair of the board of Pacira Biosciences, Inc. (NASDAQ:PCRX), a biotechnology company, and the immediate past Chair and Board Executive Committee member of the Biotechnology Innovation Organization (BIO). Mr. Hastings received a B.S. in pharmacy from the University of Rhode Island.

    Mr. Joustra is a General Partner at Forbion, a leading European life sciences venture capital firm. At Forbion, he is responsible for deal origination, general portfolio management and divestment strategies, and focuses on Forbion's Growth Opportunities Funds, which concentrates on investing in late-stage life sciences companies. Prior to joining Forbion in 2019, Mr. Joustra previously was a Senior Trader, as well as Executive Board member of the Life Sciences franchise at Kempen, a European boutique investment bank. In this role he managed Kempen's trading portfolio and was involved in deal structuring and equity capital markets transactions, as well as larger block trades.

    Mr. Joustra also served as a member of the board of directors of Gyroscope Therapeutics until the closing of its acquisition by Novartis in February 2022 for up to $1.5 billion, the board of directors of VectivBio (NASDAQ:VECT) from December 2022 until the closing of its $1.2 billion acquisition by Ironwood Pharmaceuticals in December 2023, the board of directors of Aiolos Bio until the closing of its acquisition by GSK plc in February 2024 for up to $1.4 billion and the board of Forbion European Acquisition Corporation, a special purpose acquisition company, until its completion of the business combination with enGene in October 2023.

    Currently Mr. Joustra serves on the board of directors of VectorY Therapeutics and holds a position as a board observer at NewAmsterdam Pharma N.V. (NASDAQ:NAMS). He holds an M.Sc. in Business Administration from the University of Groningen, and a B.Sc. in International Business and Management from this same university.

    About enGene

    enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene's lead program is EG-70 for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG) – a disease with a high clinical burden. EG-70 is being evaluated in an ongoing Phase 2 pivotal study. EG-70 was developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. For more information, visit enGene.com.

    Forward-Looking Statements

    Some of the statements contained in this press release may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). enGene's forward-looking statements include, but are not limited to, statements regarding enGene's expectations, hopes, beliefs, intentions, goals, strategies, forecasts and projections. The words "anticipate", "appear", "approximate", "believe", "continue", "could", "estimate", "expect", "foresee", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would", and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about: our beliefs as to the potential benefits of EG-70, the Company's plans for potential pipeline expansion, including the timing of any announcement, plans for future regulatory submissions, including the planned Biologics License Application, or BLA, for EG-70 and the expected timeline for the interim Phase 2 results from the EG-70 program.

    Many factors, risks, uncertainties and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the Company's ability to recruit and retain qualified scientific and management personnel; establish clinical trial sites and enroll patients in its clinical trials; execute on the Company's clinical development plans and ability to secure regulatory approval on anticipated timelines; and other risks and uncertainties detailed in filings with Canadian securities regulators on SEDAR+ and with the U.S. Securities and Exchange Commission ("SEC") on EDGAR, including those described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2023 and most recent Quarterly Report on Form 10-Q (copies of which may be obtained at www.sedarplus.ca or www.sec.gov).

    You should not place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. enGene anticipates that subsequent events and developments will cause enGene's assessments to change. While enGene may elect to update these forward-looking statements at some point in the future, enGene specifically disclaims any obligation to do so, unless required by applicable law. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240515759812/en/

    Get the next $ENGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENGN
    $NAMS
    $NKTX
    $PCRX

    CompanyDatePrice TargetRatingAnalyst
    Nkarta Inc.
    $NKTX
    5/15/2025Outperform → Mkt Perform
    William Blair
    enGene Holdings Inc.
    $ENGN
    2/18/2025$26.00Overweight
    Piper Sandler
    enGene Holdings Inc.
    $ENGN
    2/14/2025$34.00 → $7.00Buy → Neutral
    UBS
    Pacira BioSciences Inc.
    $PCRX
    1/30/2025$8.00 → $25.00Sell → Hold
    Truist
    NewAmsterdam Pharma Company N.V.
    $NAMS
    12/30/2024$48.00Buy
    H.C. Wainwright
    enGene Holdings Inc.
    $ENGN
    12/23/2024$25.00Buy
    H.C. Wainwright
    enGene Holdings Inc.
    $ENGN
    11/27/2024$23.00Outperform
    Raymond James
    enGene Holdings Inc.
    $ENGN
    11/18/2024$18.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $ENGN
    $NAMS
    $NKTX
    $PCRX
    Leadership Updates

    Live Leadership Updates

    See more
    • enGene Names Amy Pott as Chief Global Commercialization Officer

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC), following the completion of the pivotal co

      5/28/25 7:30:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

      Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $351.9 million on March 31, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 14, 2025

      5/14/25 4:01:00 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

      NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the

      4/17/25 4:01:00 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENGN
    $NAMS
    $NKTX
    $PCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Topper James N bought $25,521 worth of Ordinary Shares (1,135 units at $22.49) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      3/28/25 5:36:48 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $84,203 worth of Ordinary Shares (4,005 units at $21.02) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      3/6/25 5:32:07 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $4,999,993 worth of shares (561,797 units at $8.90) (SEC Form 4)

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      11/1/24 4:15:08 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    $NAMS
    $NKTX
    $PCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

      SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

      12/17/24 5:35:24 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

      SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

      12/17/24 4:00:47 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

      SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

      12/17/24 10:28:58 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENGN
    $NAMS
    $NKTX
    $PCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Pott Amy

      3 - enGene Holdings Inc. (0001980845) (Issuer)

      5/29/25 5:30:57 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Kling Douglas F exercised 100,000 units of Ordinary Shares at a strike of $10.00 and sold 100,000 units of Ordinary Shares (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      5/19/25 4:44:25 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Audet Juliette Berangere

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      5/2/25 4:56:15 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENGN
    $NAMS
    $NKTX
    $PCRX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by NewAmsterdam Pharma Company N.V.

      SCHEDULE 13G/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

      5/15/25 4:58:42 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by NewAmsterdam Pharma Company N.V.

      144 - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

      5/15/25 4:40:26 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Nkarta Inc.

      10-Q - Nkarta, Inc. (0001787400) (Filer)

      5/14/25 4:22:00 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENGN
    $NAMS
    $NKTX
    $PCRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ENGN
    $NAMS
    $NKTX
    $PCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • enGene to Present at the Jefferies Global Healthcare Conference

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 11:05 a.m. ET. A live webcast of the presentation can be accessed under the "Investors" section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene's lea

      5/29/25 8:00:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Names Amy Pott as Chief Global Commercialization Officer

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC), following the completion of the pivotal co

      5/28/25 7:30:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

      -- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 – -- An oral presentation of the data to be featured at the ASGCT Annual Meeting -- BRISBANE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new preliminary data which suggests that clinical immunogenicity does not reduce sustained improvements in knee pain, stiffness and function provided by its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), following loc

      5/15/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta downgraded by William Blair

      William Blair downgraded Nkarta from Outperform to Mkt Perform

      5/15/25 8:09:11 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on enGene Holdings with a new price target

      Piper Sandler initiated coverage of enGene Holdings with a rating of Overweight and set a new price target of $26.00

      2/18/25 7:08:31 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Holdings downgraded by UBS with a new price target

      UBS downgraded enGene Holdings from Buy to Neutral and set a new price target of $7.00 from $34.00 previously

      2/14/25 8:16:16 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    $NAMS
    $NKTX
    $PCRX
    Financials

    Live finance-specific insights

    See more
    • Pacira BioSciences Reports First Quarter 2025 Financial Results

      -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the first quarter of 2025. First Quarter 2025 Financial Highlights Total revenues of $168.9 millionNet product sales of $136.5 million for EXPAREL, $23.3 million for ZILRETTA, and $5.1 million for iovera°Net income of $4.8 million, or $0.10 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $44.1 million See "Non-GAAP Financial Informa

      5/8/25 4:00:00 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

      BRISBANE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its first quarter financial results after the close of the U.S. markets on Thursday May 8, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the confer

      4/29/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • enGene Reports First Quarter 2025 Financial Results and Provides Business Update

      Additional preliminary data from ongoing LEGEND study of detalimogene in BCG-unresponsive NMIBC with CIS, including pivotal cohort, anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026 remains on track Cash and marketable securities of $272.8 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2025, and provided a business update. "With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to track in-line with our pl

      3/10/25 4:05:00 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care